SCHEDULE: FMR LLC Reports 6.5% Stake in Royalty Pharma PLC

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, disclosing a 6.5% beneficial ownership stake in Royalty Pharma PLC's Class A Common Stock as of September 30, 2025.

Summary

• FMR LLC and Abigail P. Johnson, as reporting persons, have filed an Amendment No. 6 to Schedule 13G regarding their beneficial ownership in Royalty Pharma PLC.
• The filing reports an aggregate beneficial ownership of 27,900,713.73 shares of Class A Common Stock.
• This represents 6.5% of the total outstanding Class A Common Stock of Royalty Pharma PLC.
• FMR LLC holds sole voting power over 21,391,515.02 shares and sole dispositive power over 27,900,713.73 shares.
• Abigail P. Johnson holds sole dispositive power over 27,900,713.73 shares, with no sole or shared voting power.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
• The filing date is November 4, 2025, with the event date requiring the filing stated as September 30, 2025.

Sentiment

Score: 5

Explanation: A Schedule 13G filing is a neutral disclosure of beneficial ownership. It does not inherently convey positive or negative sentiment about the issuer's performance, but rather reflects an investment position by a major institution.

Positives

• The continued significant institutional ownership by FMR LLC, a major investment management firm, can be viewed as a vote of confidence in Royalty Pharma PLC.
• The filing explicitly states that the securities are held in the ordinary course of business and not for influencing control, suggesting a passive investment stance.

Negatives

• No specific negative information is contained within this beneficial ownership report.

Risks

• No specific risks related to Royalty Pharma PLC's operations or financial health are disclosed in this beneficial ownership filing.

Future Outlook

NA

Industry Context

This filing reflects a significant institutional stake in Royalty Pharma PLC, a company focused on acquiring pharmaceutical royalties. Such disclosures are standard for large institutional investors like FMR LLC, providing transparency into major ownership positions within publicly traded companies. The continued holding by a prominent asset manager like FMR LLC can be seen as a positive signal regarding the long-term prospects of the pharmaceutical royalty sector.

Comparison to Industry Standards

• Institutional ownership of 6.5% by a major asset manager like FMR LLC is a common occurrence in the public markets.
• While no specific comparable companies or projects are mentioned in the filing, large institutional holdings are typical for established companies in the biotechnology and pharmaceutical sectors, indicating investor confidence and liquidity.
• This level of ownership is consistent with what one might expect from a large, diversified investment firm holding a position in a company like Royalty Pharma PLC.

Related Party Transactions

• FMR LLC and Abigail P. Johnson are the reporting persons, with Abigail P. Johnson being a Director, Chairman, and Chief Executive Officer of FMR LLC.
• Members of the Johnson family, including Abigail P. Johnson, are predominant owners of Series B voting common shares of FMR LLC, representing 49% of its voting power.
• The Johnson family group and other Series B shareholders have a voting agreement, allowing the family to be deemed a controlling group for FMR LLC under the Investment Company Act of 1940.
• This structure clarifies the relationship between the individual and the institutional reporting entity.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like FMR LLC may instill confidence among existing and potential shareholders, signaling a belief in the company's value.
• Management: Awareness of a large institutional holder can influence management's strategic decisions and communication, emphasizing accountability.
• Regulatory Authorities: The filing ensures transparency regarding significant ownership, fulfilling regulatory requirements for market oversight.

Next Steps

• NA

Key Dates

Keywords

Royalty Pharma PLC, FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Class A Common Stock, Institutional Investor, Pharmaceutical Royalties, Investment Management